TWI680139B - 短胜肽、及其組合物用於治療/預防糖尿病及與之相關疾病之用途 - Google Patents
短胜肽、及其組合物用於治療/預防糖尿病及與之相關疾病之用途 Download PDFInfo
- Publication number
- TWI680139B TWI680139B TW107125276A TW107125276A TWI680139B TW I680139 B TWI680139 B TW I680139B TW 107125276 A TW107125276 A TW 107125276A TW 107125276 A TW107125276 A TW 107125276A TW I680139 B TWI680139 B TW I680139B
- Authority
- TW
- Taiwan
- Prior art keywords
- pharmaceutical composition
- treating
- item
- patent application
- scope
- Prior art date
Links
- 206010012601 diabetes mellitus Diseases 0.000 title claims 5
- 108090000765 processed proteins & peptides Proteins 0.000 title claims 4
- 201000010099 disease Diseases 0.000 title claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims 3
- 239000000203 mixture Substances 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 208000013600 Diabetic vascular disease Diseases 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 201000009101 diabetic angiopathy Diseases 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 230000017074 necrotic cell death Effects 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 230000008929 regeneration Effects 0.000 claims 1
- 238000011069 regeneration method Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (5)
- 一種一胜肽用於製備促進胰島再生之醫藥組合物之用途，其中，該胜肽之胺基酸序列係由包含有SEQ ID No.2所示序列所組成。
- 依據申請專利範圍第1項所述用途，其中，該醫藥組合物係用於治療糖尿病。
- 依據申請專利範圍第1項所述用途，其中，該醫藥組合物係用於治療或/及預防高糖誘發心臟病變。
- 依據申請專利範圍第3項所述用途，其中，該醫藥組合物係更包含有另一胜肽，其胺基酸序列係為SEQ ID No.1。
- 依據申請專利範圍第1項所述用途，其中，該醫藥組合物係用於預防或治療一由糖尿病所引發之疾病，而該由糖尿病引發疾病係選自由糖尿病血管病變、糖尿病肝臟病變、糖尿病腎病及胰島壞死所組成之群。
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW107125276A TWI680139B (zh) | 2018-07-21 | 2018-07-21 | 短胜肽、及其組合物用於治療/預防糖尿病及與之相關疾病之用途 |
| CN201811100774.6A CN110746487B (zh) | 2018-07-21 | 2018-09-20 | 短胜肽、及其组合物用于治疗/预防糖尿病及与之相关疾病的用途 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW107125276A TWI680139B (zh) | 2018-07-21 | 2018-07-21 | 短胜肽、及其組合物用於治療/預防糖尿病及與之相關疾病之用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TWI680139B true TWI680139B (zh) | 2019-12-21 |
| TW202007695A TW202007695A (zh) | 2020-02-16 |
Family
ID=69275648
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW107125276A TWI680139B (zh) | 2018-07-21 | 2018-07-21 | 短胜肽、及其組合物用於治療/預防糖尿病及與之相關疾病之用途 |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN110746487B (zh) |
| TW (1) | TWI680139B (zh) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160228503A1 (en) * | 2013-09-25 | 2016-08-11 | Pronutria, Inc. | Compositions and Formulations for Prevention and Treatment of Diabetes and Obesity, and Methods of Production and Use Thereof in Glucose and Caloric Control |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001049834A2 (en) * | 2000-01-06 | 2001-07-12 | Monsanto Technology Llc | Preparation of deallergenized patatin proteins and patatin permutein proteins |
| TWI588153B (zh) * | 2012-05-18 | 2017-06-21 | 中國醫藥大學 | 多胜肽、編碼該多胜肽之核酸分子、以及該多胜肽之應用 |
| CN105566459A (zh) * | 2014-10-08 | 2016-05-11 | 吴辅佑 | 可抑制RAGE与Aβ的结合或能与Aβ/RAGE结合的富脯胺酸胜肽及其制备方法 |
| TWI624477B (zh) * | 2016-07-05 | 2018-05-21 | Peptide composition and use thereof |
-
2018
- 2018-07-21 TW TW107125276A patent/TWI680139B/zh active
- 2018-09-20 CN CN201811100774.6A patent/CN110746487B/zh active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160228503A1 (en) * | 2013-09-25 | 2016-08-11 | Pronutria, Inc. | Compositions and Formulations for Prevention and Treatment of Diabetes and Obesity, and Methods of Production and Use Thereof in Glucose and Caloric Control |
Non-Patent Citations (1)
| Title |
|---|
| Huang et al. "Potato protein hydrolysate attenuates high fat diet-induced cardiac apoptosis through SIRT1/ PGC-1á/Akt signaling" journal of functional foods 12 ( 2 0 1 5 ) 389–398 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110746487B (zh) | 2023-12-12 |
| CN110746487A (zh) | 2020-02-04 |
| TW202007695A (zh) | 2020-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017532343A5 (zh) | ||
| JP2020507623A5 (zh) | ||
| PE20220938A1 (es) | Compuestos agonistas de gipr | |
| JPWO2019156137A5 (zh) | ||
| JP2009017881A5 (zh) | ||
| JP2018511327A5 (zh) | ||
| TWI455721B (zh) | 癌疫苗組合物 | |
| JPWO2019107530A5 (zh) | ||
| JP2018538356A5 (zh) | ||
| JP2005537234A5 (zh) | ||
| JP2015517489A5 (zh) | ||
| JP2017532965A5 (zh) | ||
| JP2016536357A5 (zh) | ||
| CN110799522A (zh) | 用于治疗、改善或预防脑出血的肽及其用途 | |
| JP2018504112A5 (zh) | ||
| JP2017521074A5 (zh) | ||
| JP2019513752A5 (zh) | ||
| RU2017114673A (ru) | Слитый белок, наночастица, состоящая из множества мономеров указанного слитого белка, и их применение | |
| JP2007535910A5 (zh) | ||
| JP2017500316A5 (zh) | ||
| KR20180037185A (ko) | 광범위의 항감염성 펩티드 | |
| JP2009500045A5 (zh) | ||
| JP2020117504A5 (zh) | ||
| JP2014519514A5 (zh) | ||
| JP2010512326A5 (zh) |